Jiangsu Hengrui Medicine Co., Ltd.
600276.SS

$40.25 B
Marketcap
$6.34
Share price
Country
$-0.04
Change (1 day)
$7.89
Year High
$4.87
Year Low

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.

marketcap

P/S ratio for Jiangsu Hengrui Medicine Co., Ltd. (600276.SS)

P/S ratio as of 2023: 12.54

According to Jiangsu Hengrui Medicine Co., Ltd.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 12.54. At the end of 2022 the company had a P/S ratio of 11.53.

P/S ratio history for Jiangsu Hengrui Medicine Co., Ltd. from 1997 to 2023

P/S ratio at the end of each year

Year P/S ratio
2023 12.54
2022 11.53
2021 12.49
2020 21.29
2019 16.54
2018 11.20
2017 11.59
2016 8.02
2015 8.58
2014 5.24
2013 5.80
2012 4.77
2011 5.06
2010 8.26
2009 7.49
2008 5.78
2007 8.81
2006 7.52
2005 1.36
2004 1.19
2003 0.87
2002 1.45
2001 2.43
2000 4.35
1999 4.67
1998 5.32
1997 6.37